Catalyzing early-stage life science companies
Supporting scientists, clinicians, and entrepreneurs with a passion to transform life science research or healthcare
Rose Ventures works with early-stage companies developing innovative, high-impact life science products and services. We bring a wealth of direct operational expertise, a track record of success, and a network of life scientists, entrepreneurs, and contacts in industry, academia, finance, and government that can be leveraged to facilitate growth of the most promising emerging companies in the life science space. Beyond financing or advisory services, we benefit portfolio companies and clients by tapping into a network that can help them execute their business plans and create value for all stakeholders.
Available Now
A story of the relentless pursuit of one’s passion, this memoir reveals the impact of inevitable, unexpected events on a business and life. Dr. Rose shares approaches for navigating past unanticipated challenges and embracing unforeseen opportunities to achieve successful outcomes.
Stan Rose, PhD
President and managing partner Dr. Stan Rose is a biologist, life sciences executive, and serial entrepreneur. He has spent over three decades working with leading scientists and clinicians to create substantial commercial value from inventions related to DNA and genome analysis. He has raised more than $100 million in start-up funding and led businesses to create more than $1 billion in market value for shareholders, commercializing life science products impacting the lives of millions. He is the author of Can’t Tame a Mongoose: Memoir of a Genomics Entrepreneur.
Dr. Rose currently serves on the board of Xeno Biosciences, a drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. Dr. Rose is also a cofounding director of a stealth start-up in the oncology therapeutics space. He serves as a senior fellow with the Council on Strategic Risks, participating in the Alliance to End Biological Threats, and as an advisor to Bristlecone Pacific, a venture fund focused on early-stage companies across the longevity ecosystem.
Dr. Rose was cofounder, president, and CEO of Transplant Genomics Inc. (acquired by Eurofins in 2019), whose TruGraf blood gene-expression tests enable doctors to rule out silent rejection in kidney-transplant recipients.
Dr. Rose was a director of Cellular Dynamics International (NASDAQ: ICEL, acquired by FujiFilm in 2015), a leader in pluripotent stem cell technology for drug discovery and cell therapy, and chair of the Market Advisory Board for CyVek, a protein immunoassay and immuno-diagnostics company (acquired by Bio-Techne in 2014).
Highlights from earlier in his career include serving as CEO of NimbleGen Systems, a genomics tools company, from 2003 through its acquisition by Roche in 2007; cofounding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s.
Dr. Rose received his BA from Cornell University and his PhD from the Massachusetts Institute of Technology.
Contact: stan@roseventures.net
Contact
Email: Info@roseventures.net
